Table 4.
The predictive capacity of the HCT-CI compared with ACE-27 and CCI for NRM, relapse, and survival among all patients as assessed by Cox regression models taking into account other risk factors
| Index/comorbidity group | Relapse |
NRM |
Survival |
|||
|---|---|---|---|---|---|---|
| HR* | P | HR* | P | HR* | P | |
| HCT-CI | .01 | <.00 | <.00 | |||
| Low | 1.0 | 1.0 | 1.0 | |||
| Intermediate | 2.74 | 3.95 | 3.68 | |||
| High | 2.67 | 7.16 | 5.60 | |||
| ACE-27 | .13 | .27 | .22 | |||
| Low | 1.0 | 1.0 | 1.0 | |||
| Intermediate | 1.54 | 1.53 | 1.59 | |||
| High | 2.10 | 0.69 | 1.23 | |||
| CCI | .03 | .08 | .01 | |||
| Low | 1.0 | 1.0 | 1.0 | |||
| Intermediate | 0.92 | 2.49 | 2.09 | |||
| High | 2.46 | 2.06 | 2.25 | |||
NRM indicates nonrelapse mortality; and HR, hazard ratio.
*
HR was adjusted for age, stem-cell source, cytogenetic risk, donor type, conditioning type, and institution type.